|
491
|
| 2329 |
ADIPOQ
|
|
increases_activity of
|
fatty acid beta-oxidation
|
in muscle
|
|
12368907
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,924
|
| 14795 |
LEP
|
|
affects_activity of
|
inflammatory response
|
|
|
19087258
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,083
|
| 16820 |
Reactive oxygen species
|
|
increases_activity of
|
polyol pathway
|
|
|
10783895
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,088
|
| 16827 |
hyperglycemia
|
|
increases_quantity of
|
Advanced glycation end-product
|
|
|
10082470
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,814
|
| 26084 |
ADIPOQ
|
|
decreases_activity of
|
angiogenesis
|
|
| 129691 |
inflammatory response
|
|
increases_activity of
|
angiogenesis
|
|
|
21912508
|
Diabetes mellitus, type II
Cancer
Insulin resistance
Metabolic syndrome
|
|
3,107
|
| 28533 |
LEP
|
|
increases_activity of
|
lipid catabolic process
|
in white adipose tissue
|
| 28548 |
LEP
|
|
increases_activity of
|
receptor signaling pathway via JAK-STAT
|
in brown adipose tissue, in white adipose tissue
|
|
9389752
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,557
|
| 33063 |
Diabetes mellitus, type II
|
|
increases_activity of
|
incomplete fatty acid beta-oxidation
|
|
|
19369366
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
5,929
|
| 55976 |
hyperglycemia
|
|
decreases_quantity of
|
ADIPOQ
|
|
|
24167545
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,660
|
| 129652 |
incomplete fatty acid beta-oxidation
|
|
increases_activity of
|
abnormal mitochondrial physiology
|
|
|
26108617
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,890
|
| 67279 |
Nephropathy, diabetic
|
|
increases_activity of
|
increased urine protein level
|
|
|
27284338
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
6,900
|
| 68023 |
Diabetes mellitus, type II
|
|
increases_activity of
|
abnormal mitochondrial physiology
|
|
|
27127460
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,191
|
| 82495 |
extracellular matrix assembly
|
|
increases_activity of
|
Nephropathy, diabetic
|
|
| 82500 |
extracellular matrix assembly
|
|
increases_activity of
|
decreased renal glomerular filtration rate
|
|
|
26043887
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
8,481
|
| 86787 |
hexosamine biosynthetic pathway
|
|
affects_activity of
|
oxidative phosphorylation
|
in adipose tissue, in muscle
|
| 86788 |
hexosamine biosynthetic pathway
|
|
affects_expression of
|
LEP
|
in adipose tissue
|
|
15466941
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,020
|
| 117768 |
renin-angiotensin system
|
|
increases_activity of
|
regulation of blood pressure
|
|
| 117774 |
renin-angiotensin system
|
|
affects_activity of
|
renal fibrosis
|
|
| 117780 |
renin-angiotensin system
|
|
affects_activity of
|
extracellular matrix organization
|
|
| 117781 |
renin-angiotensin system
|
|
affects_activity of
|
inflammatory response
|
|
| 117783 |
renin-angiotensin system
|
|
increases_quantity of
|
Angiotensin II
|
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,178
|
| 119364 |
complement activation
|
|
affects_activity of
|
innate immune response
|
|
|
32544563
|
COVID-19
|
|
13,185
|
| 125090 |
cilium
|
|
increases_activity of
|
sensory perception of mechanical stimulus
|
|
|
24861006
|
Diabetes mellitus, type II
Insulin resistance
Ciliopathy
|
|
13,241
|
| 125445 |
ADIPOQ
|
|
decreases_activity of
|
albuminuria
|
in diabetic patients
|
|
28402446
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
13,242
|
| 125462 |
ADIPOQ
|
|
decreases_quantity of
|
Reactive oxygen species
|
via ADIPOR1 and AMPK
|
| 125463 |
ADIPOQ
|
|
decreases_activity of
|
abnormal podocyte physiology
|
|
| 125472 |
ADIPOQ
|
|
decreases_activity of
|
response to oxidative stress
|
|
| 125474 |
ADIPOQ
|
|
decreases_activity of
|
inflammatory response
|
|
| 125479 |
ADIPOQ
|
|
decreases_activity of
|
renal fibrosis
|
|
|
28402446
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
13,275
|
| 125593 |
hyperglycemia
|
|
increases_activity of
|
kidney failure
|
|
| 125598 |
Advanced glycation end-product
|
|
increases_activity of
|
kidney failure
|
|
| 125603 |
toll-like receptor signaling pathway
|
|
increases_activity of
|
NF-kappaB complex
|
|
| 125607 |
toll-like receptor 4 signaling pathway
|
|
increases_activity of
|
renal fibrosis
|
|
| 125645 |
Nephropathy, diabetic
|
|
affects_activity of
|
complement activation
|
|
|
31942046
|
Nephropathy, diabetic
|
|
13,349
|
| 125955 |
hyperglycemia
|
|
increases_activity of
|
extracellular matrix assembly
|
in mesangial cells
|
|
7924884
|
Nephropathy, diabetic
|
|
13,378
|
| 126062 |
extracellular matrix assembly
|
|
increases_activity of
|
glomerulosclerosis
|
in patients with diabetic nephropathy
|
| 126073 |
toll-like receptor 2 signaling pathway
|
|
affects_activity of
|
extracellular matrix assembly
|
in patients with diabetic nephropathy
|
| 126074 |
toll-like receptor 4 signaling pathway
|
|
affects_activity of
|
extracellular matrix assembly
|
in patients with diabetic nephropathy
|
|
26119175
|
Nephropathy, diabetic
|
|
13,412
|
| 126421 |
Advanced glycation end-product
|
|
increases_quantity of
|
Reactive oxygen species
|
in mesangial cells; via AGER
|
| 129657 |
Advanced glycation end-product
|
|
affects_activity of
|
renin-angiotensin system
|
|
| 129658 |
Advanced glycation end-product
|
|
affects_activity of
|
renal fibrosis
|
in mesangial cells
|
|
15569303
|
Nephropathy, diabetic
|
|
13,430
|
| 126633 |
renin-angiotensin system
|
|
affects_activity of
|
inflammatory response
|
|
|
28616206
|
Immunological
Nephropathy, diabetic
|
|
13,474
|
| 127022 |
NF-kappaB complex
|
|
affects_activity of
|
angiogenesis
|
|
|
25474138
|
Hepatocellular carcinoma
Cancer
|
|
13,489
|
| 127110 |
Nephropathy, diabetic
|
|
increases_activity of
|
expanded mesangial matrix
|
|
| 127112 |
Nephropathy, diabetic
|
|
increases_activity of
|
increased renal glomerulus basement membrane thickness
|
|
| 127113 |
Nephropathy, diabetic
|
|
increases_activity of
|
decreased podocyte number
|
|
| 127114 |
Nephropathy, diabetic
|
|
increases_activity of
|
glomerulosclerosis
|
|
| 127116 |
Nephropathy, diabetic
|
|
increases_activity of
|
decreased renal glomerular filtration rate
|
|
| 127119 |
hypertension
|
|
increases_activity of
|
Nephropathy, diabetic
|
|
| 127121 |
renin-angiotensin system
|
|
increases_activity of
|
Nephropathy, diabetic
|
|
| 127135 |
response to oxidative stress
|
|
increases_activity of
|
polyol pathway
|
|
| 127142 |
response to oxidative stress
|
|
increases_quantity of
|
Advanced glycation end-product
|
|
| 127208 |
hexosamine biosynthetic pathway
|
|
increases_activity of
|
NF-kappaB complex
|
|
| 127210 |
hexosamine biosynthetic pathway
|
|
increases_activity of
|
inflammatory response
|
|
| 127224 |
polyol pathway
|
|
increases_quantity of
|
Advanced glycation end-product
|
|
| 127225 |
Advanced glycation end-product
|
|
increases_activity of
|
inflammatory response
|
|
| 127226 |
Advanced glycation end-product
|
|
increases_activity of
|
NF-kappaB complex
|
|
| 127290 |
Reactive oxygen species
|
|
increases_activity of
|
receptor signaling pathway via JAK-STAT
|
|
|
32098346
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
13,497
|
| 127237 |
coagulation
|
|
affects_activity of
|
Nephropathy, diabetic
|
|
|
20307901
|
Nephropathy, diabetic
|
|
13,508
|
| 127378 |
Reactive oxygen species
|
|
increases_activity of
|
extracellular matrix assembly
|
|
|
26719364
|
Nephropathy, diabetic
|
|
13,621
|
| 128183 |
Nephropathy, diabetic
|
|
increases_activity of
|
complement activation
|
|
| 128186 |
complement activation
|
|
affects_quantity of
|
Reactive oxygen species
|
|
|
32161193
|
Immunological
Nephropathy, diabetic
|
|
13,669
|
| 128409 |
innate immune response
|
|
increases_activity of
|
macrophage activation
|
|
| 128412 |
innate immune response
|
|
increases_activity of
|
NLRP3 inflammasome
|
|
| 128413 |
Advanced glycation end-product
|
|
increases_activity of
|
NLRP3 inflammasome
|
|
| 128423 |
innate immune response
|
|
increases_activity of
|
complement activation, lectin pathway
|
|
|
28760771
|
Nephropathy, diabetic
|
|
13,674
|
| 128446 |
ADIPOQ
|
|
decreases_activity of
|
macrophage activation
|
via binding to C1qRp, the receptor for C1q
|
|
10961870
|
Immunological
|
CIDeRplus